Prima technology showing positive results
30 April, 2002 by Tanya HollisPrima Biomed's (ASX: PRR) vaccine platform technology has taken another step towards success by triggering a strong immune response in large animals, the company reported today.
Wilmut disappointed, others happy with cloning progress
30 April, 2002 by Melissa TrudingerRecent media interviews with Dr Ian Wilmut, the scientist responsible for cloning Dolly the sheep, have suggested that all clones are genetically and physically defective.
McGauran promises action on killer jellyfish research
30 April, 2002 by Iain ScottScience Minister Peter McGauran has pledged his support to a call for funding to research the tiny irukandji jellyfish, which has claimed two lives off the Queensland coast this year.
New bio-investor launches IPO
29 April, 2002 by Tanya HollisAustralia's latest biotech share offering opens this week when device and diagnostics investment company Premier Bionics launches its IPO.
ES Cell scores US grant, license deal
29 April, 2002 by Tanya HollisMelbourne's ES Cell International has scored a double coup in the United States with the awarding of a National Institutes of Health infrastructure grant and the signing of a research licensing deal.
BresaGen wins NIH deal
26 April, 2002 by Tanya HollisA second Australian company has won the right to provide embryonic stem cell lines to the National Institutes of Health (NIH) in the United States.
Dwarf grapes may revolutionise viticulture
26 April, 2002 by Melissa TrudingerAustralian scientists have discovered a mutation in grapevines equivalent to the dwarfing mutation in cereals discovered in the 1960s that was the basis of the "green revolution", which saw an increase in wheat yields.
GE-free zones inhibit farmers' freedom: Avcare
24 April, 2002 by Daniella GoldbergFarmers need to be given freedom to grow their choice of crops - GM, organic or conventional - and this freedom is inhibited by GE-free zones being imposed by certain councils and local governments, according to Avcare.
Ellex teams with US on laser deal
24 April, 2002 by Iain ScottA new deal with US firm Lumenis will allow South Australian company Ellex Medical Lasers to design, develop and manufacture a range of lasers to treat secondary cataracts and glaucoma.
Jellyfish deaths spark research call
23 April, 2002 by Iain ScottThe recent deaths of two tourists thought to have been stung by tiny, previously unknown species of jellyfish off tropical Queensland beaches has sparked a call for extensive research funding.
GroPep revises forecast, now predicts loss
23 April, 2002 by Tanya HollisDrug discovery group GroPep (ASX: GRO) has forecast a $4 million loss this year despite predicting profits of $1.9 million for 2001-02 just two months ago.
Polartechnics wins design awards
23 April, 2002 by Daniella GoldbergSydney-based biotechnology company Polartechnics has came out on top with two design awards for its cervical cancer detection device, TruScan.
Cryosite's IPO closes oversubscribed
23 April, 2002 by Daniella GoldbergCryogenic storage of umbilical cord blood has been given the thumbs up by Australian investors, with today's announcement that Cryosite's IPO closed early and oversubscribed.
Never the twain? GM and organic farming go head to head
22 April, 2002 by Melissa TrudingerThe co-existence of genetically modified (GM) and organic farming was hotly debated at a meeting hosted by the Life Sciences Network last week.
NZ turns to microbes to fight methane levels
22 April, 2002 by Daniella GoldbergNew Zealand's pastoral sector is planning to pool its resources in a new bid to reduce the amount of methane gas emissions from the country's livestock.
